Registered entities
Revance Therapeutics, Inc.,
Reg. No. 77-0551645United States
Revance Therapeutics, Inc.
Reg. No. 1479290United States
Revance Therapeutics, Inc.
Reg. No. 001t000000scXuxAAEUnited States
Innovation
55 patent families (32 granted) — focus: Human necessities, Chemistry & metallurgy, Operations & transport, Emerging technologies; filing pace steady. Cited 7,901 times.
| Year | Filings |
|---|---|
| 2015 | 16 |
| 2016 | 18 |
| 2017 | 19 |
| 2018 | 14 |
| 2019 | 16 |
| 2020 | 18 |
| 2021 | 15 |
| 2022 | 10 |
| 2023 | 8 |
| 2024 | 10 |
| 2025 | 10 |
| 2026 | 5 |
Investor mix
18 investors on record; lead investors include Delphi Ventures, EW Healthcare Partners, NovaQuest Capital Management, Medicis Pharmaceutical; 2 have since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 5 | 28% |
| Private equity | 5 | 28% |
| Angel & family office | 1 | 6% |
| Bank & private debt | 4 | 22% |
| Other / undisclosed | 3 | 17% |
Hiring activity
No recent openings observed
No roles tracked in the last 12 months
30 May 2025 · Quality Assurance Specialist · Oakland
22 May 2025 · Professional Aesthetic Consultant - Hawaii · Honolulu
Based on job postings tracked across public sources.